Brant K. Oelschlager

Brant K. Oelschlager

Auto-generated profile, based on publicly available information

Brant K. Oelschlager

Department of Surgery, University of Washington, Seattle, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2011 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
BOBrant K. Oelschlager
Brant K. Oelschlager
CPCarlos A. Pellegrini
Carlos A. Pellegrini
JHJohn G. Hunter
John G. Hunter
MBMichael L. Brunt
Michael L. Brunt
NSNathaniel J. Soper
Nathaniel J. Soper
LSLee L. Swanstrom
Lee L. Swanstrom
In 2006, we reported results of a randomized trial of laparoscopic paraesophageal hernia repair (LPEHR), comparing primary diaphragm repair (PR) with primary repair buttressed with a biologic prosthesis (small intestinal submucosa [SIS]). The primary endpoint, radiologic hiatal hernia (HH) recurrence, was higher with PR (24%) than with SIS buttressed repair (9%) after 6 months. The second phase of this trial was designed to determine the long-term durability of biologic mesh-buttressed repair. We systematically searched for the 108 patients in phase I of this study to assess current clinical symptoms, quality of life (QOL) and determine ongoing durability of the repair by obtaining a follow-up upper gastrointestinal series (UGI) read by 2 radiologists blinded to treatment received. HH recurrence was defined as the greatest measured vertical height of stomach being at least 2 cm above the diaphragm. At median follow-up of 58 months (range 42 to 78 mo), 10 patients had died, 26 patients were not found, 72 completed clinical follow-up (PR, n = 39; SIS, n = 33), and 60 repeated a UGI (PR, n = 34; SIS, n = 26). There were 20 patients (59%) with recurrent HH in the PR group and 14 patients (54%) with recurrent HH in the SIS group (p = 0.7). There was no statistically significant difference in relevant symptoms or QOL between patients undergoing PR and SIS buttressed repair. There were no strictures, erosions, dysphagia, or other complications related to the use of SIS mesh. LPEHR results in long and durable relief of symptoms and improvement in QOL with PR or SIS. There does not appear to be a higher rate of complications or side effects with biologic mesh, but its benefit in reducing HH recurrence diminishes at long-term follow-up (more than 5 years postoperatively) or earlier.

1 August 2005 in Journal of Laparoendoscopic & Advanced Surgical Techniques
Verified
Journal Article
Closed access
JKJedediah A. Kaufman
Jedediah A. Kaufman
CPCarlos A. Pellegrini
Carlos A. Pellegrini
BOBrant K. Oelschlager
Brant K. Oelschlager
Morbid obesity is a disease encompassing multiple, significant comorbidities. The only current, reliable, durable treatment of obesity is surgical intervention, most commonly gastric bypass. Achalasia, a swallowing disorder of esophageal motility and failure of the lower esophageal sphincter (LES) to relax, is rarely seen in the morbidly obese patient. Treatment is directed at disruption of the LES to allow passage of food. As medical management usually fails in both disease processes, surgical treatment is often chosen. The patient with both morbid obesity and achalasia presents an unusual challenge for surgical treatment. The standard surgical approach for each disease does not address the other, and may have deleterious consequences on the other condition if approached unilaterally. We present the first case of a patient treated with a concomitant laparoscopic esophagogastric myotomy (LEM) and laparoscopic Roux-en-Y gastric bypass (LRYGBP).

1 January 2010 in World Journal of Gastroenterology
Verified
Journal Article
Open access
EWEelco B Wassenaar
Eelco B Wassenaar
BOBrant K Oelschlager
Brant K Oelschlager
Barrett’s esophagus (BE) is a change in the esophageal mucosa as a result of long-standing gastroesophageal reflux disease. The importance of BE is that it is the main risk factor for the development of esophageal adenocarcinoma, whose incidence is currently growing faster than any other cancer in the Western world. The aim of this review was to compare the common treatment modalities of BE, with the focus on proton pump inhibitors and operative fundoplication. We performed a literature search on medical and surgical treatment of BE to determine eligible studies for this review. Studies on medical and surgical treatment of BE are discussed with regard to treatment effect on progression and regression of disease. Although there is some evidence for control of reflux with either medical or surgical therapy, there is no definitive evidence that either treatment modality decreases the risk of progression to dysplasia or cancer. Even though there is a trend toward antireflux surgery being superior, there are no definitive studies to prove this.

17 June 2014 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
EMEllen Morrow
Ellen Morrow
DBDaniel Bushyhead
Daniel Bushyhead
EWEelco Wassenaar
Eelco Wassenaar
MHMarcelo Hinojosa
Marcelo Hinojosa
MLMaximiliano Loviscek
Maximiliano Loviscek
BOBrant Oelschlager
Brant Oelschlager

1 February 2011 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
SKSaurabh Khandelwal
Saurabh Khandelwal
RPRebecca Petersen
Rebecca Petersen
RTRoger Tatum
Roger Tatum
HSHuseyin Sinan
Huseyin Sinan
DADaniel Aaronson
Daniel Aaronson
BOBrant K. Oelschlager
Brant K. Oelschlager

19 October 2022 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
RCRocio E. Carrera Ceron
Rocio E. Carrera Ceron
RYRobert B. Yates
Robert B. Yates
AWAndrew S. Wright
Andrew S. Wright
HRH. Alejandro Rodriguez
H. Alejandro Rodriguez
RLRebecca G. Lopez
Rebecca G. Lopez
BOBrant K. Oelschlager
Brant K. Oelschlager